ThredUp

ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.

Quarterly,Results,Company,Income,Profits,Sales,Update,Report,3d,Illustration

Analyst Color

News

Analyst Ratings

BBWI

BURL

ROST

SFIX

TDUP

WRBY

Telsey Advisory Group analyst Dana Telsey on Tuesday provided an overview of which consumer sectors were the best performers in the third-quarter and highlighted some &#34;stocks with potential.&#34;

Warby Parker, RH, Bath &amp; Body Works Are &#39;Stocks With Potential,&#39; Analyst Says

penny stocks tips 1

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

PIII

XWEL

ThredUp And 2 Other Stocks Under $2 Executives Are Buying

movers image

Movers

AVGO

BLMZ

BOWL

CLNN

EAST

FFIE

GWRE

HOTH

SIFY

SWBI

WHLR

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

ThredUp Inc

WIIM

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q4 financial results.

Management

CBUS

Cibus President And COO Appointed As Interim CEO; Succeeds Rory Riggs

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

Price Target

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Biotech

General

Nexalin Technology To Begin Patient Recruitment For UCSD's TBI & PTSD Clinical Study

Financing

TRIB

Trinity Biotech Announces Additional $4M Funding

BFLY

Butterfly Network shares are trading lower. The company reported Q4 financial results.

ADGM

Adagio Medical Announces Strategic Restructuring To Accelerate IDE Trial And Product Innovation

Macro Economic Events

Econ #s

Economics

USA Personal Spending (MoM) For January -0.2% Vs 0.2% Est.; 0.8% Prior

USA PCE Price Index (YoY) For January 2.5% Vs 2.5% Est.; 2.6% Prior

PCE price index (MoM) (Jan) +0.3% vs +0.3% Est.; Prior +0.3%

USA Core PCE Price Index (YoY) For January 2.6% Vs 2.6% Est.; 2.9% Prior

Macro Notification

USA Core PCE Price Index (MoM) For Jan. 0.3% Vs 0.3% Est. Vs 0.2% Prior

Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Overweight and lowers the price target from $53 to $48.

Piper Sandler Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $48

Definitiv Healthcare shares are trading lower after the company issued FY25 and Q1 guidance below estimates.

Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Neutral and lowers the price target from $7.5 to $6.

IOVA

Piper Sandler Maintains Neutral on Iovance Biotherapeutics, Lowers Price Target to $6

DCGO

DocGo shares are trading lower after the company reported worse-than-expected Q4 financial results.

CUBE

CubeSmart shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and sales estimates.

Piper Sandler analyst Sean Wieland maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Overweight and raises the price target from $25 to $40.

PRVA

Piper Sandler Maintains Overweight on Privia Health Gr, Raises Price Target to $40

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/TGT/earnings">opening bell, on Tuesday, March 4.</a>
Analysts expect the retailer to report quarterly earnings at $2.25 per share, down from $2.98 per share in the year-ago period. Target projects quarterly revenue of $30.85 billion, compared to $31.92 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 26, JP Morgan analyst Christopher Horvers maintained Target with a Neutral and raised the price target from $139 to $146.
With the recent buzz around Target, some investors may be eyeing potential gains from the company's dividends too. As of now, Target offers an annual dividend yield of 3.61%, which is a quarterly dividend amount of $1.12 per share ($4.48 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $164,028 or around 1,339 shares. For a more modest $100 per month or $1,200 per year, you would need $32,830 or around 268 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.48 in this case). So, $6,000 / $4.48 = 1,339 ($500 per month), and $1,200 / $4.48 = 268 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
TGT Price Action: Shares of Target fell 1.2% to close at $122.50 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>
Photo: Shutterstock

Earnings

How To Earn $500 A Month From Target Stock Ahead Of Q4 Earnings

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $75 to $84.

SOLV

Piper Sandler Maintains Neutral on Solventum, Raises Price Target to $84

Press Releases

ThredUp Releases Third Annual Impact Report

ThredUp Launches Suite of AI Shopping Features

ThredUp Announces Second Quarter 2024 Results

ThredUp to Report Third Quarter 2024 Financial Results on November 4, 2024

ThredUp Announces Third Quarter 2024 Results

ThredUp Appoints Danielle Vermeer as Head of Social Commerce

ThredUp Completes Divestiture of European Business

ThredUp to Participate in Needham Conference

ThredUp Provides Preliminary Fourth Quarter 2024 Results, Exceeding Guidance

ThredUp to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

American Eagle Outfitters, Inc. Common Stock

American Eagle Outfitters

Abercrombie & Fitch

Buckle

Boot Barn Holdings

Burlington Stores

Caleres

Citi Trends

Torrid Holdings

Designer Brands Inc. Class A Common Stock

Designer Brands

Foot Locker

Genesco

Guess

J.Jill

Lands' End

MYT Netherlands Parent B.V. American Depositary Shares, each representing one Ordinary Share

Comments

ThredUp

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga